`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`
`BAUSCH HEALTH IRELAND LIMITED
`Patent Owner.
`
`_____________________________
`
`
`
`Case IPR2022-01104
`Patent 9,919,024
`_____________________________
`
`MYLAN PHARMACEUTICALS INC.’S
`UPDATED NOTICE UNDER
`37 C.F.R. § 42.8(a)(3)
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. (Mylan) submits the following
`
`mandatory change-of-information notices for IPR2022-01104.
`
`A.
`
`Real Party-In-Interest (37 C.F.R. § 42.8(b)(1)) – Unchanged
`
`Petitioner Mylan Pharmaceuticals Inc. (“Mylan”) is a co-defendant with Mylan
`
`Laboratories Ltd., Mylan Inc., and Viatris Inc. in parallel litigation.
`
`Although Agila Specialties Inc. and Mylan API US LLC were also named as
`
`defendants in the administratively-closed Western District of Pennsylvania litigation
`
`(see below), they are not real parties-in-interest. They were dismissed from the case
`
`now in the Northern District of West Virginia and were the subject of a motion to
`
`dismiss when the Pennsylvania case was administratively closed.
`
`B.
`
`Related Matters (37 C.F.R. § 42.8(b)(2)) – Updated
`
`Mylan Pharmaceuticals Inc. v. Bausch Health Ireland Ltd., IPR2022-00722
`
`(PTAB) (IPR2023-00016 joined); and Bausch Health Ireland Ltd. v. Mylan
`
`Laboratories Ltd., 1-22-cv00020 (NDWV); 2-21-cv-00573 (WDPA) (administratively
`
`closed); and Bausch Health Ireland Ltd. v. MSN Laboratories Pvt. Ltd., 2-21-cv-
`
`10057 (DNJ). IPR2022-01102, IPR2022-01103, and IPR2022-01105 involve patents
`
`closely related to the challenged patent.
`
`Patent owner Bausch has identified pending application 17/207,222 (under
`
`final rejection) as related.
`
`-2-
`
`
`
`C.
`
`Lead and Back-up Counsel (37 C.F.R. § 42.8(b)(3)) – Updated
`
`Lead:
`
`Jad Mills, Reg. No. 63,344.
`
`First Backup:
`
`Richard Torczon, Reg. No. 34,448.
`
`Backup:
`
`
`
`Nicole Stafford, Reg. No. 43,929, and1
`
`Dennis Gregory, Reg. No. 52,967.
`
`Postal Address:
`
`701 Fifth Avenue, Suite 5100, Seattle, WA 98104-7036.
`
`Telephone:
`
`206-883-2554.
`
`Facsimile:
`
`
`
`206-883-2699.
`
`D.
`
`Electronic Service - Updated
`
`Mylan consents to electronic-mail service at: jmills@wsgr.com,
`
`rtorczon@wsgr.com, dgregory@wsgr.com, and 4881-7825-
`
`5901@mail.vault.netdocuments.com.
`
`Date: 20 March 2023
`
`/Richard Torczon/
`Richard Torczon, Reg. No. 34,448
`Counsel for Mylan Pharmaceuticals, Inc.
`
`1 No longer at Wilson Sonsini.
`
`-3-
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that today this paper was served on the Patent Owner at the Patent
`
`Owner’s email correspondence addresses as follows:
`
`Justin J. Hasford
`
`Bryan C. Diner
`
`justin.hasford@finnegan.com
`
`bryan.diner@finnegan.com
`
`Joshua L. Goldberg
`
`joshua.goldberg@finnegan.com
`
`Kassandra M. Officer
`
`kassandra.officer@finnegan.com
`
`Lauren J. Robinson
`
`lauren.robinson@finnegan.com
`
`Caitlin E. O’Connell
`
`caitlin.o’connell@finnegan.com
`
`Kyu Yun Kim
`
`kyuyun.kim@finnegan.com
`
`Date: March 20, 2023
`
`Respectfully submitted,
`
`/Robyn Moriarty/
`Robyn Moriarty
`
`-4-
`
`